TQB2450 + cisplatin + carboplatin + 5-fluorouracil

TQB2450 + cisplatin + carboplatin + 5-fluorouracil is an investigational multi-agent combination therapy consisting of TQB2450 (a PD-L1 inhibitor), cisplatin (a platinum-based cytotoxic chemotherapy), carboplatin (another platinum-based chemotherapy), and 5-fluorouracil (an antimetabolite chemotherapy) administered intravenously for the treatment of advanced malignant tumors. - **TQB2450** is a humanized IgG1 monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), blocking its binding to PD-1 and CD80, and thus enhancing T cell antitumor activity[1]. - **Cisplatin** and **carboplatin** are platinum coordination complexes that cause DNA crosslinking and apoptosis in rapidly dividing tumor cells. - **5-fluorouracil** (5FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA and RNA synthesis in cancer cells[3]. This combination is under investigation for various advanced solid tumors, exploiting immune checkpoint blockade and cytotoxic chemotherapy mechanisms.